Skip to content

Effect of oral Magnesium in diabetic neuropathy

Analyzing the effect of oral magnesium on (NDS)Neuropathy Disability Score of peripheral neuropathy in type 2 diabetes patients among subjects of Loghman Hakim Hospital clinic in Tehran

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20230522058258N1
Enrollment
60
Registered
2024-08-04
Start date
2024-07-29
Completion date
Unknown
Last updated
2024-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peripheral polyneuropathy in type 2 diabetes. Type 2 diabetes mellitus with diabetic polyneuropathy

Interventions

Sponsors

Shahid Beheshti University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 85 Years

Inclusion criteria

Inclusion criteria: Men and women between the ages of 20 and 85 Having type 2 diabetes (whose type 2 diabetes has already been proven by tests of FBS > 126 and HbA1c > 6.5 and they are being treated with oral antidiabetic drugs or insulin) Having the symptoms of distal peripheral polyneuropathy: feeling pain and excessive sensitivity or reduced sensation or feeling of burning, tingling and murmur in the hands or feet of the patient

Exclusion criteria

Exclusion criteria: Suffering from other neuropathies other than diabetic neuropathy Neuromuscular diseases (such as myasthenia gravis) Magnesium level above 2.1 History of magnesium consumption in the last 3 months A history of persistent diarrhea and vomiting History of diuretic use with a dose of more than 40 mg History of thyroid diseases or levothyroxine use History of heart block or use of calcium channel blockers Having chronic kidney disease (GFR<60) Taking antidepressants, anticonvulsants, or analgesics Pregnancy and breastfeeding History of any malignancy History of amputation or active diabetic foot ulcer

Design outcomes

Primary

MeasureTime frame
Vibration sensation. Timepoint: Before the intervention and 1 and 2 months after the intervention. Method of measurement: Duration of perception of vibration sensation in the big toe of both feet after the 128 Hz diapason is placed on the big toe of both feet of the patient.;Temperature sensation. Timepoint: Before the intervention and 1 and 2 months after the intervention. Method of measurement: Placing a cold fork on the patient's cheek and comparing the perception of the same cold temperature on the big toe of both feet.;Pin-prick sensation. Timepoint: Before the intervention and 1 and 2 months after the intervention. Method of measurement: Assess whether the patient can differentiate between the sharp and neutral ends of the appropriate pin on the dorsum of the toe and whether they can anatomically grasp a cotton swab in the same location.;Ankle reflex. Timepoint: Before the intervention and 1 and 2 months after the intervention. Method of measurement: Impacting below the knee in a sitting position by reflex hammer and evaluating reflex and response of quadriceps muscle.;NDS score (Neuropathy Disability Score). Timepoint: Before the intervention and 1 and 2 months after the intervention. Method of measurement: Collecting the patient's points in vibration, pin-prick, temperature, and ankle reflex tests for both lower limbs, which can be a number between 0 and 10.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactArezoo Ranjbar Arani

Shahid Beheshti University of Medical Sciences

arezoo.ranjbar@sbmu.ac.ir+98 21 5541 7243

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026